別品名 |
HWA-486, Arava, 5-Methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide
|
別包装 |
あり
|
純度 |
>=98%
|
分子量 |
270.21
|
CAS RN® |
75706-12-6
|
化合物の概要 |
AhR agonist, dihydroorotate dehydrogenase inhibitor.
|
構造 |
C12H9F3N2O2
|
溶媒 |
Soluble in DMSO or methanol.
|
使用目的 |
Leflunomide inhibits dihydroorotate dehydrogenase, preventing UMP formation and pyrimidine synthesis. Metabolites of leflunomide may inhibit various kinases such as JNK and JAK. Leflunomide is clinically used to treat rheumatoid arthritis; it exhibits immunosuppressive, antiviral, and anticancer activities. In several cellular models, leflunomide prevents apoptosis and increases viability in human cytomegalovirus (CMV)-infected cells and inhibits replication of polyomavirus BK. Additionally, leflunomide increases activity of aryl hydrocarbon receptors, inhibiting proliferation of melanoma cells.
|
その他 |
[融点]166.5℃ [外観]White or off-white crystalline powder
|
参考文献 |
Qi R, Hua-Song Z, Xiao-Feng Z. Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus. Eur J Med Res. 2013 Feb 1;18:3. PMID: 23369524.O'Donnell EF, Kopparapu PR, Koch DC, et al. The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells. PLoS One. 2012;7(7):e40926. PMID: 22815870.Bernhoff E, Tylden GD, Kjerpeseth LJ, et al. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J Virol. 2010 Feb;84(4):2150-6. PMID: 19955306.Pinto P, Dougados M. Leflunomide in clinical practice. Acta Reumatol Port. 2006 Jul-Sep;31(3):215-24. PMID: 17094333.
|
※サムネイル画像をクリックすると拡大画像が表示されます。
|
|
|
メーカー |
品番 |
包装 |
LKT
|
L1817
|
500 MG
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
1週間程度
|
保存温度 |
-20℃
|
|